CD8A and neoplasm: found that DC101 and an anti-PD-L1 drug had synergistic effects in murine models of breast cancer (MMTV-PyMT), glioblastoma (NFpp10-GBM), and pancreatic neuroendocrine tumors (RT2-PNET), and the combination could increase IFN-γ+CD8+T cells, trigger tumor regression, and substantially improve survival rates (129).